Lyell Immunopharma, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · South San Francisco, CA
LYEL chart
What traders are saying about $LYEL
Latest postsLyell Immunopharma, Inc. news
- Lyell Immunopharma at Stifel 2026 Healthcare Conference: ronde-cel push By Investing.com
Investing.com UK ·
- Lyell Immunopharma, Inc. reports results for the quarter ended September 30 - Earnings Summary
TradingView ·
- Lyell Immunopharma, Inc. expected to post a loss of $2.14 a share - Earnings Preview
TradingView ·
- Latham Advises on Lyell Immunopharma’s US$80 Million Private Placement
Legal Desire ·
- Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy
marketbeat.com ·
- Form 4 Lyell Immunopharma Inc: ARCH Venture Fund XIII, L.P. (10% Owner) For: 4 November
Investing.com Nigeria ·
- At $10.77 a share, ARCH Venture Fund XIII buys Lyell Immunopharma (LYEL) stock.
Stock Titan ·
- At $10.77 a share, ARCH Venture Fund XIII buys stock in Lyell Immunopharma (LYEL).
Stock Titan ·
- Why Did Lyell Immunopharma (NASDAQ:LYEL) Jump 43% as Nurix (NASDAQ:NRIX), CVS Health (NYSE:CVS), Centene (NYSE:CNC) and Rhythm Pharmaceuticals (NASDAQ:RYTM) Also Moved on November 4 and 5?
Kalkine ·
- Why Did Lyell Immunopharma (NASDAQ:LYEL) Gain 43% on a 77% Complete Response Rate?
Kalkine ·
- What Do Lyell Immunopharma's (NASDAQ:LYEL) Updated Ronde-Cel Results Reveal Ahead of ASH 2026?
Kalkine ·
- Lyell Immunopharma: Q3 Earnings Snapshot
Yahoo Finance ·
Lyell Immunopharma, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $36,000 | $61,000 | $130,000 | $84.7M |
| Net income | -$274.4M | -$343.0M | -$234.6M | -$183.1M |
| Diluted EPS | $-16.06 | $-26.23 | $-18.70 | $-0.74 |
| Total assets (year end) | $340.1M | $490.9M | $750.0M | $937.6M |
| Cash and equivalents (year end) | $60.2M | $105.6M | $145.6M | $123.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Lyell Immunopharma, Inc.
- Ticker
- LYEL (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1806952
Frequently asked questions
What exchange is Lyell Immunopharma, Inc. listed on?
Lyell Immunopharma, Inc. trades on the Nasdaq under the ticker symbol LYEL.
What industry is Lyell Immunopharma, Inc. in?
Lyell Immunopharma, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Lyell Immunopharma, Inc. headquartered?
Lyell Immunopharma, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Lyell Immunopharma, Inc.'s fiscal year end?
Lyell Immunopharma, Inc.'s fiscal year ends on December 31.
How much revenue did Lyell Immunopharma, Inc. report?
Lyell Immunopharma, Inc. reported $36,000 in revenue for calendar year 2025, according to its SEC filings.